Introduction: Patients with familial hypercholesterolemia (FH) are at increased risk of premature atherosclerotic cardiovascular disease (ASCVD). Aim of study: To perform a retrospective analysis of data to assess the effects of individual lipoproteins and other risk factors (RFs) on the development of ASCVD and to compare these parameters in individuals with versus without ASCVD. Patients and methods: Our study group included a total of 1,236 patients with FH (395 men and 841 women with a mean age of 44.8 ± 16.7 years) attending a single lipid clinic. The diagnosis of FH was established using the Dutch Lipid Clinic Network score (DLCN). Among the 1236 FH patients, 1,008 of them [854 suspected with LDL receptor-mediated FH and 154 with familial defective apolipoprotein B-100 (FDB)] were genetically analysed. Their RFs were assessed based on the patients' clinical characteristics. Results: While patients with ASCVD had higher baseline LDL-C, TC, TG and Lp(a) compared with patients without this diagnosis, this ratio was just the opposite by the follow-up. The highest statistically significant differences were seen in the baseline levels of Lp(a) and, quite surprisingly, TG. Except for Lp(a), the levels of all lipid parameters declined significantly over time. While the incidence of diabetes and arterial hypertension was not higher in our group compared with the general population, these patients were at a more significant risk of ASCVD. Conclusion: Familial hypercholesterolemia is a major RF for the development of ASCVD. While our analysis confirmed the important role of LDL-C, it also corroborated a strong correlation between ASCVD and other lipid parameters, and Lp(a) and TG in particular. Familial hypercholesterolemia is not the only RF and, to reduce cardiovascular risk of their patients, physicians have to search for other potential RFs. Patients diagnosed to have FH benefit from attending a specialized lipid clinic perse.

3rd Department of Medicine Department of Endocrinology and Metabolism of the 1st Faculty of Medicine Charles University and General University Hospital Prague Czechia

Zobrazit více v PubMed

Altschmiedova T., Todorovova V., Snejdrlova M., Satny M., Ceska R. (2020). PCSK9 Inhibitors in Real-World Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology. Curr. Atheroscler. Rep. – January 12, 2022 accepted for publication. PubMed PMC

Beheshti S. O., Madsen C. M., Varbo A., Nordestgaard B. G. Worldwide Prevalence of Familial Hypercholesterolemia. J. Am. Coll. Cardiol. 2020; 75(20): 2553–2566. 10.1016/j.jacc.2020.03.057 PubMed DOI

Borén J., Chapman M. J., Krauss R. M., Packard C. J., Bentzon J. F., Binder C. J., et al. (2020). Low-density Lipoproteins Cause Atherosclerotic Cardiovascular Disease: Pathophysiological, Genetic, and Therapeutic Insights: a Consensus Statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 41 (24), 2313–2330. 10.1093/eurheartj/ehz962 PubMed DOI PMC

Ceska R., Vrablik M., Altschmiedova T., Prusíková M., Urbanová Z., Šobra J. (2014). Familial Hypercholesterolemia – Past and Present: Our Experiences and Findings in Our Group of Patients with Familial Hypercholesterolemia. Vnitř Lék 60 (11), 963–969. english abstract is available: www.casopisvnitrnilekarstvi.cz/pdfs/vnl/2014/11/10.pdf . PubMed

Ceska R., Latkovskis G., Ezhov M. V., Freiberger T., Lalic K., Mitchenko O., et al. (2019). The Impact of the International Cooperation on Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project. Curr. Atheroscler. Rep. 21 (9), 36. PMID: 31230174; PMCID: PMC6589142. 10.1007/s11883-019-0797-3 PubMed DOI PMC

Cífková R., Bruthans J., Wohlfahrt P., Krajčoviechová A., Šulc P., Jozífová M., et al. (2020). 30-year Trends in Major Cardiovascular Risk Factors in the Czech Population, Czech MONICA and Czech post-MONICA, 1985 - 2016/17/17. PLoS One 15 (5), e0232845. e0232845. 10.1371/journal.pone.0232845 PubMed DOI PMC

Cífková R., Bruthans J., Wohlfahrt P., Krajčoviechová A., Šulc P., Eremiášová L., et al. (2020). (The Prevalence of Major Cardiovascular Risk Factors in the Czech Population in 2015-2018. The Czech post-MONICA Study). Cor Vasa 62, 6–16. english abstract available. 10.33678/cor.2020.010 DOI

Civeira F., Perez-Calahorra S., Mateo-Gallego R. (2016). Rapid Resolution of Xanthelasmas after Treatment with Alirocumab. J. Clin. Lipidol. 10 (5), 1259–1261. 10.1016/j.jacl.2016.07.007 PubMed DOI

Ference B. A., Ginsberg H. N., Graham I., Ray K. K., Packard C. J., Bruckert E., et al. (2017). Low-density Lipoproteins Cause Atherosclerotic Cardiovascular Disease. 1. Evidence from Genetic, Epidemiologic, and Clinical Studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 38 (32), 2459–2472. PMID: 28444290; PMCID: PMC5837225. 10.1093/eurheartj/ehx144 PubMed DOI PMC

Hoogeveen R. C., Ballantyne C. M. (2021). Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. Clin. Chem. 67 (1), 143–153. PMID: 33257928; PMCID: PMC7793228. 10.1093/clinchem/hvaa252 PubMed DOI PMC

Jackevicius C. A., Mamdani M., Tu J. V. (2002). Adherence with Statin Therapy in Elderly Patients with and without Acute Coronary Syndromes. JAMA 288 (4), 462–467. PMID: 12132976. 10.1001/jama.288.4.462 PubMed DOI

Nordestgaard B. G., Chapman M. J., Humphries S. E., Ginsberg H. N., Masana L., Descamps O. S., et al. (2013). Familial Hypercholesterolaemia Is Underdiagnosed and Undertreated in the General Population: Guidance for Clinicians to Prevent Coronary Heart Disease: Consensus Statement of the European Atherosclerosis Society. Eur. Heart J. 34, 3478–3490a. 10.1093/eurheartj/eht273 PubMed DOI PMC

O'Donoghue M. L., Fazio S., Giugliano R. P., Stroes E. S. G., Kanevsky E., Gouni-Berthold I., et al. (2019). Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation 139 (12), 1483–1492. PMID: 30586750. 10.1161/CIRCULATIONAHA.118.037184 PubMed DOI

Šobra J. (1970). Familiární Hypercholesterolemická Xanthomatosa. Praha: Avicenum.

Sun D., Li S., Zhao X., Wu N.-Q., Zhu C.-G., Guo Y.-L., et al. (2018). Association between Lipoprotein (A) and Proprotein Convertase Substilisin/kexin Type 9 in Patients with Heterozygous Familial Hypercholesterolemia: A Case‐control Study. Metabolism 79, 33–41. Epub 2017 Nov 10. PMID: 29129821. 10.1016/j.metabol.2017.11.004 PubMed DOI

The Lipid Research Clinics Coronary Primary Prevention Trial results (1984). The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in Incidence of Coronary Heart Disease. JAMA 251 (3), 351–364. 10.1001/jama.1984.03340270029025 PubMed DOI

Todorovova V., Altschmiedova T., Vrablik M., Ceska R. (2022). Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetics and Biochemical Parameters. Front. Genet. 13, 849008. 10.3389/fgene.2022.849008 PubMed DOI PMC

van der Steeg W. A., Holme I., Boekholdt S. M., Larsen M. L., Lindahl C., Stroes E. S. G., et al. (2008). High-Density Lipoprotein Cholesterol, High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for Cardiovascular Risk. J. Am. Coll. Cardiol. 51 (6), 634–642. 10.1016/j.jacc.2007.09.060 PubMed DOI

Versmissen J., Oosterveer D. M., Yazdanpanah M., Defesche J. C., Basart D. C., Liem A. H., et al. Efficacy of Statins in Familial Hypercholesterolaemia: a Long Term Cohort Study. BMJ. 2008;337, a2423:a2423. 10.1136/bmj.a2423 PMID: 19001495; PMCID: PMC2583391 PubMed DOI PMC

Visseren F. L. J., Mach F., Smulders Y. M., Carballo D., Koskinas K. C., Bäck M., et al. (2021). 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Eur. Heart J. 42 (34, 7), 3227–3337. 10.1093/eurheartj/ehab484 PubMed DOI

Watts G. F., Ding P. Y., George P., Hagger M. S., Hu M., Lin J., et al. (2016). Translational Research for Improving the Care of Familial Hypercholesterolemia: The "Ten Countries Study" and beyond. Jat 23 (8), 891–900. Epub 2016 Jul 6. PMID: 27384016; PMCID: PMC7399296. 10.5551/jat.35949 PubMed DOI PMC

Zhou B., Bentham J., Di Cesare M., Bixby H., Danaei G., Cowan M. J., et al. (2017). Worldwide Trends in Blood Pressure from 1975 to 2015: a Pooled Analysis of 1479 Population-Based Measurement Studies with 19·1 Million Participants. Lancet 389 (10064), 37–55. Epub 2016 Nov 16. Erratum in: Lancet. 2020 Sep 26;396(10255):886. PMID: 27863813; PMCID: PMC5220163. 10.1016/S0140-6736(16)31919-5 PubMed DOI PMC

Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetics and Biochemical Parameters